Fluxion Biosciences Awarded $1.8 million NIH Grant for Development of High-Throughput Screening Platform.Microfluidic Design Enables High-Throughput Anti-microbial Screening SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif. -- Fluxion fluxion /flux·ion/ (fluk´shun) a flowing; especially an abnormal or excessive flow of fluid to a part. fluxion, n Biosciences, a leading developer of microfluidic systems for functional cell analysis, today announced that it has received a $1.8 million NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. grant for the development of a high-throughput screening High-throughput screening (HTS), is a method for scientific experimentation especially used in drug discovery and relevant to the fields of biology and chemistry. Purpose and method platform for anti-microbial drug discovery. The Phase II grant will enable the company to further develop its innovative microfluidic platform for cellular research and drug discovery. The Phase II project will build on the successful proof-of-concept results from the Phase I grant, which identified a high-throughput screening approach for anti-microbial drugs. Antibiotics such as penicillin, tetracycline tetracycline (tĕ'trəsī`klēn), any of a group of antibiotics produced by bacteria of the genus Streptomyces. They are effective against a wide range of Gram positive and Gram negative bacteria, interfering with protein , and amoxicillin amoxicillin /amox·i·cil·lin/ (ah-mok?si-sil´in) a semisynthetic derivative of ampicillin effective against a broad spectrum of gram-positive and gram-negative bacteria. a·mox·i·cil·lin n. have been around for decades. Over time, certain microbes have developed resistance to these treatments. Drug-resistant infections cause 14,000 deaths in America each year and add over $4 billion in cost to the healthcare system. The latest grant focuses on the integration of the drug screening approach developed during the Phase I research into a fully automated platform. The system, based on high-throughput functional screening on live bacteria or cells, is expected to have additional application in the development of drugs for treatment of cardiovascular and immune disorders. "We are pleased to receive this Phase II NIH grant for the continued development of this exciting screening platform," said Cristian Ionescu-Zanetti, Ph.D., chief technology officer. "The results of our Phase I project showed significant gains over conventional drug screening approaches. This platform promises to be a powerful tool for developing the next generation of drug therapies." About Fluxion Biosciences Fluxion Biosciences provides cellular analysis tools for use in critical life science research and drug discovery applications. Fluxion's proprietary microfluidic platform enables precise functional analysis of individual cells in a multiplexed format. Fluxion's systems meet the rigorous demands of life science and drug discovery scientists by providing an intuitive, easy-to-use operating system operating system (OS) Software that controls the operation of a computer, directs the input and output of data, keeps track of files, and controls the processing of computer programs. for single-cell biology. For more information about Fluxion Biosciences, visit www.fluxionbio.com. |
|
|||||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion